AML
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
AML
Jul 20, 2024, 14:27 |
Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 |
Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
Jul 19, 2024, 13:19 |
Insight
Sanam Loghavi: Optical genome mapping in acute myeloid leukemia
Sanam Loghavi, shared a post on X about a recent paper titled "Optical genome mapping improves…
Jul 15, 2024, 12:11 |
Insight
Finishing the MMPCC series for 2023-24 with Joe Maakaron
Alain Mina, Assistant research physician of Immune Deficiency Cellular Therapy Program at NIH-NCI, shared on…
Jul 15, 2024, 06:09 |
Insight
Naveen Pemmaraju: Superb talk on developing immune-targeting agents in AML
Naveen Pemmaraju shared on X: "Absolutely superb talk by Dr Yasmin Abaza at AML-ALL US…
Jul 13, 2024, 19:41 |
Insight
Joshua Zeidner: Subset analyses from QUAZAR study
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about a recent paper by…
Jul 12, 2024, 16:59 |
Insight
Naveen Pemmaraju: Two of the finest people I have ever known
Naveen Pemmaraju shared a post on X: “Just landed MD Education AML-ALL US Focus meeting…
Jul 9, 2024, 00:57 |
Insight
Talha Badar: Outcome after stopping venetoclax and azacitidine
Talha Badar shared on X: “American Journal of Hematology, Blood Research Journal, Wiley Online Library.…
Jul 8, 2024, 16:34 |
Insight
Aref Al-Kali: AML is hanging with use of FLT3i and Allo BMT
Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared on X: "Outcome of t6;9 AML changing with…
Jul 6, 2024, 11:09 |
Insight
Therapeutic time window from diagnosis to treatment for elderly AML patients
Matteo Molica, Hematologist Medical Director at UOC Hematology Oncohaematology Department at the Apulian Ciaccio Hospital,…
Jun 28, 2024, 14:06 |
Blog
Vincent Rajkumar: Cure is a simple word. But there is confusion when it comes to cancer
Vincent Rajkumar shared a post on X: “Cure is a simple word. But there is…
Jun 24, 2024, 13:16 |
Insight
Hagop Kantarjian: NPM1-mutant myeloid neoplasms should be treated with AML-type treatment
Hagop Kantarjian shared on X: . "NPM1-mutant myeloid…
Jun 21, 2024, 12:25 |
Blog
Sanam Loghavi: Another day in the life of a hematopathologist
Sanam Loghavi shared on X/Twitter: "Another day in the life of a hematopathologist….. To say I…
Jun 21, 2024, 05:21 |
Blog
Mikkael A. Sekeres: The circle of academic hematology life
Mikkael A. Sekeres, Chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, shared…
Jun 18, 2024, 23:17 |
Insight
Talha Badar: TP53 mutation in Myeloproliferative neoplasms
Talha Badar shared on X: , "Genomic landscape, impact allelic burden, time to…
Jun 18, 2024, 23:01 |
Insight
Dr. Naval Daver presented results of ENHANCE-3 study at EHA2024
Talha Badar shared on X: . "Dr. Naval Daver: Presented results of…
Jun 18, 2024, 14:51 |
Insight
Amer Zeidan: Our newest paper on 61 TP53-mutated AML
Amer Zeidan shared on X: "Our newest paper with a detailed Integrated analysis of genetic,…
Jun 18, 2024, 11:23 |
Blog
Wafik S. El-Deiry: Informative presentation by John Reagan about “MyeloMATCH"
Wafik S. El-Deiry shared on LinkedIn: . "Very informative…
Jun 11, 2024, 14:59 |
Insight
Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, CEO of LucidQuest shared a post on LinkedIn: “EHA24 is fast approaching and…
May 22, 2024, 04:26 |
Blog
Warren Fingrut: 2nd-ever Health Disparities in Hematologic Malignancies Conference
Warren Fingrut, Hematologist and Stem Cell Transplant physician at MD Anderson Cancer Center, posted on…
May 19, 2024, 09:37 |
Blog
Eline Bertrums on International collaborations and Genetic Insights in Childhood Cancer
Eline Bertrums, Physician assistant (ANIOS) pediatrics at Gelderland Valley Hospital, shared a post on LinkedIn:…
May 14, 2024, 15:10 |
Blog
Naval Daver shares updates on novel emerging therapies in AML - MD Anderson Cancer Center
MD Anderson Cancer Center shared on X: “There’s much more optimism and hope that we…
May 14, 2024, 10:12 |
Blog
Aaron Goodman: CD markers simplified!
Quoting Aaron Goodman on X: “CD markers simplified! CD34+ = Blast CD3+ = T-cell CD19+ = B-cell…
May 13, 2024, 13:11 |
Insight
Justin Kaner: To transplant or not to transplant…..
Justin Kaner, Assistant Professor of the Leukemia Program at Weill Cornell, shared on X: "To…
May 12, 2024, 07:00 |
Blog
Ellen Madarang: We proved that treatment of 80-90 year olds with AML can be done
Ellen Madarang, Hematology Oncology Clinical Pharmacist at Sylvester Comprehensive Cancer Center, shared the following post…
May 12, 2024, 06:02 |
Insight
Rasoul Pourebrahim: Our latest publication on studying mutant p53-driven Acute Myeloid Leukemia
Rasoul Pourebrahim, Assistant Professor at MD Anderson, made the following post on LinkedIn: "Our paper…
May 12, 2024, 01:40 |
Insight
Justin Watts: A significant portion of patients at the extremes of older age (80-90) still derive benefit from the VEN-HMA regimen
Justin Watts et al. report that standard of care treatment for acute myeloid leukemia extends…
May 7, 2024, 01:32 |
Blog
AML session at HOPLive24 - Blood Cancers Today
Blood Cancers Today shared on X/Twitter: "Up next: Naval Daver, Sanam Loghavi, Rami Komrokji, and Mikkael…
May 1, 2024, 21:39 |
Blog
It’s the one-two punch cancer treatment that ‘floats like a butterfly, and STINGs like a bee’! - WEHI (Walter and Eliza Hall Institute of Medical Research)
WEHI (Walter and Eliza Hall Institute of Medical Research) made the foll0wing post on LinkedIn:…
Apr 28, 2024, 13:17 |
Blog
Emad Bin Zahid: Annie Im is one of the global leaders in the field of hematology-oncology
Emad Bin Zahid, Student at Tbilisi State Medical University, shared a post on LinkedIn: “Annie…
Apr 28, 2024, 11:34 |
Insight
Talha Badar: Clinical significance of RAS mutation in AML
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center, shared a post on X:…
Apr 27, 2024, 14:29 |
Opinion
Amer Zeidan: I find MRD literature increasingly confusing as it pertains to decision making
Amer Zeidan shared a post on X: "I have to say I find MRD literature…
Apr 21, 2024, 09:04 |
Blog
Naveen Pemmaraju: Brilliant talk Leukemia Wed noon Grand Rounds by Dr. Sanam Loghavi on new applications of Optical Genome Mapping (OGM) in AML!
Naveen Pemmaraju posted on X/Twitter: "Brilliant talk today MD Anderson Cancer Center Leukemia Wed noon…
Apr 21, 2024, 06:16 |
Dialogues
Oncodaily Dialogues #8 Mikkael Sekeres/ Hosted by Roupen Odabashian
In our ongoing series called “OncoDaily Dialogues”, we consistently feature prominent individuals in the field of…
Apr 19, 2024, 20:20 |
Drugs
This new review article is all about Tagraxofusp for BPDCN - ACS Journal Cancer
ACS Journal Cancer recently shared on X: "This new review article from Wei Ying Jen,…
Apr 12, 2024, 11:59 |
Insight
Wei Zhang: Congratulations to an outstanding physician scientist Tim Pardee for the new R21 grant that addresses health disparities in acute myeloid leukemia
Wei Zhang, Director at Center for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer…
Apr 5, 2024, 08:22 |
Insight
Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Mar 23, 2024, 04:57 |
Insight
Alicia Perzolli: Happy to share my first publication for my Ph.D. at Princess Máxima Center for Pediatric Oncology about 'Targeting the innate immune system in pediatric and adult AML'
Mar 10, 2024, 20:49 |
Insight
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University…
Mar 4, 2024, 10:16 |
Blog
Hagop Kantarjian: Gamma delta T cells, a novel immunotherapy for AML
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD…
Feb 15, 2024, 11:28 |
Blog
Sanam Loghavi: The fabulous Dr. Miles and her poster and data on BRAF- mutated AML at SCT24
Sanam Loghavi shared a post on X/Twitter: “The fabulous Dr. Miles and her poster and…
Feb 8, 2024, 05:16 |
Insight
Hagop Kantarjian: A new standard of care in newly diagnosed older FLT3-mutated AML
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
Feb 2, 2024, 05:57 |
Blog
Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML
Mark Geyer, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, recently shared on X/Twitter:…
Jan 19, 2024, 18:49 |
Blog
Natalia Baran: Amazing work on targeting mitochondrial GPX4-mediated ferroptosis in AML authored by Hiroki Akiyama and supervised by Joe Ishizawa
Natalia Baran, Assistant Professor in the Department of Leukemia at the UT MD Anderson Cancer…
Jan 9, 2024, 19:11 |
Blog
Talha Badar: What is the right duration of VENETOCLAX with HMA for AML
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Jan 5, 2024, 17:36 |
Insight
Talha Badar: What is the right duration of Venetoclax with HMA for AML?
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, shared on X/Twitter:…
Dec 29, 2023, 16:10 |
Blog
Amalia Aleck: 'Someone has been giving our smoldering MM patients MDS and AML! Let’s GOOOOOOOO!'
Amalia Aleck, Anesthesiologist at Valley Anesthesiology Consultants, tweeted on X/Twitter: "Everyone: it’s a good time of…
Dec 24, 2023, 18:42 |
Insight
Naveen Pemmaraju: Important new paper led by Alex Bataller and Tapan Kadia
Naveen Pemmaraju shared on X/Twitter: "Important New paper just out in Blood Advances led by…
Dec 23, 2023, 15:43 |
Blog
Aaron Goodman: How I do AML induction 1 tweet
Aaron Goodman shared a post on X/Twitter: “How I do AML induction 1 tweet (it's not…
Dec 19, 2023, 18:10 |
Positive
Amer Zeidan: And the call we had tonight made my week...
Amer Zeidan shared on X/Twitter: "One of my patients established a tradition where he and…
Dec 12, 2023, 18:26 |
Blog
Talha Badar: Our abstract studying immune clustering via CyTOF in AML pts receiving VEN+HMA
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Dec 1, 2023, 19:13 |
Insight
V. Lokesh Battula: Our findings on resistance to Fluorothymidine 3 inhibitors in Acute Myeloid Leukemia are now published in the Leukemia Journal
V. Lokesh Battula, Associate Professor at MD Anderson Cancer Center, shared on LinkedIn: "Happy to…
Nov 20, 2023, 03:53 |
Insight
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on…
Nov 13, 2023, 13:43 |
Drugs
Jayastu Senapati: Check out the commentary to our paper in the Blood Journal by Paresh Vyas
Jayastu Senapati, Leukemia fellow at MD Anderson Cancer Centre, shared on X/Twitter: "Check out the…
Nov 11, 2023, 17:32 |
Opinion
Aaron Goodman: I have strong opinions on FLT3i maintenance post allogeneic transplant
Aaron Goodman shared a post by Wolver Heme on X/Twitter: "I have strong opinions on…
Oct 4, 2023, 17:21 |
Insight
Registration is open for this year’s EHASWG Scientific Meeting on MDS/MPN/AML- Kordasti Lab.
Quoting Kordasti Lab on X/Twitter: “Interested in MDS, MPN, or AML? Registration is open for…
Oct 1, 2023, 16:29 |
Blog
Tracey O'Brien: At the Cancer Institute New South Wales (NSW), we’re proud to support incredible New South Wales researchers like Nunki Hassan.
Tracey O'Brien, New South Wales Chief Cancer Officer, shared a post by Cancer Institute New…
Sep 27, 2023, 18:06 |
Drugs
Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.
Sep 22, 2023, 19:09 |
Insight
Daniel De Carvalho: We propose the ratio of IFN/LSC as a biomarker and target in MPN-sAML progression.
Quoting Daniel De Carvalho, Co-founder and Chief Scientific Officer at Adela and Professor at Princess…
Sep 19, 2023, 02:41 |
Insight
Learn how scientists are unlocking the secrets of genetic rearrangements in childhood leukemia and pioneering new treatments. - St. Baldrick's Foundation
Quoting St. Baldrick's Foundation on LinkedIn: "Exciting Research Update! Children battling acute myeloid leukemia (AML)…
Sep 17, 2023, 16:54 |
Opinion
Andres Gomez: In my view, the most important issue for AML patients worldwide is lack of access to comprehensive testing.
Quoting Andres Gomez, Associate Professor at UANL Monterrey, Mexico, on X/Twitter: "I like the paper…
Sep 3, 2023, 17:31 |
Insight
Jayastu Senapati: A small effort highlighting the challenges in the care of patients with AML in LMICs - The Lancet Haematology
Jayastu Senapati, a clinical fellow, at MD Anderson Cancer Center, recently tweeted: "A small effort…
Sep 1, 2023, 18:38 |
Drugs
Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.
Hagop Kantarjian, Department Chair, Department of Leukemia, Division of Cancer Medicine at MD Anderson Cancer…
Aug 27, 2023, 19:01 |
Insight
Naveen Pemmaraju: New paper alert from our group led by our doctor Montalban Bravo and professor Garcia Manero.
Quoting Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center,…
Jul 22, 2023, 02:20 |
Opinion
If I happened to get 10 new AML patients in one night - Amer Zeidan
Quoting Amer Zeidan on Twitter, "If I happened to get 10 new AML patients in…
Jul 18, 2023, 19:39 |
Drugs
Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML
Quoting Hagop Kantarjian on Twitter, "MD Anderson Cancer Center's Leukemia researchers identify the use of venetoclax…
Jun 3, 2023, 16:53 |
Blog
Study Reveals Discrepancies in Access to Potentially Curative HCT for Eligible AML Patients - ASCO Daily News
“Findings from this project demonstrate inferior outcomes in our cohort of patients with AML, partly…
All:
67
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube